Physician profile
Anna Ng
NPI 1508047127
$11,253.76
in general payments reported to CMS, 2019-2025
29 companies · $2,631 in 2025
The $2,631 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,987 · 2022: $1,914 · 2023: $2,050 · 2024: $2,672 · 2025: $2,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,944 · Education: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,944.29 |
| Education | $408.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,012.23 | 2021-2025 | |
| Janssen Biotech, INC. | $1,202.73 | 2021-2025 | Tremfya, Stelara, Remicade |
| Lilly USA, LLC | $992.27 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $920.53 | 2021-2025 | Winlevi, Absorica Ld |
| Ucb, INC. | $800.15 | 2021-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $734.97 | 2021-2024 | Siliq, Cabtreo, Duobrii |
| Incyte Corporation | $703.03 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $554.02 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $548.79 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $484.62 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $457.85 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $389.41 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $329.80 | 2023-2024 | Zoryve |
| Genzyme Corporation | $207.09 | 2021-2024 | |
| Galderma Laboratories, L.P. | $170.37 | 2021-2025 | Nemluvio, Aklief |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $165.85 | 2021-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.03 | 2022-2024 | Spevigo |
| Almirall LLC | $127.90 | 2021 | |
| Botanix Sb INC | $52.79 | 2025 | Sofdra |
| Pacira Pharmaceuticals Incorporated | $41.02 | 2022 | |
| Verrica Pharmaceuticals INC. | $34.45 | 2024 | Ycanth |
| Organon LLC | $32.18 | 2025 | Vtama |
| Genentech USA, INC. | $29.31 | 2022 | |
| Biofrontera INC. | $29.13 | 2021-2022 | |
| Dermavant Sciences, INC. | $29.10 | 2024 | Vtama |
| Epi Health, LLC | $26.52 | 2021 | |
| Krystal Biotech INC | $22.30 | 2023 | Vyjuvek |
| Sandoz INC. | $16.23 | 2025 | Hyrimoz |
| Vyne Pharmaceuticals INC. | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.